Introduction
============

Primary hepatocellular carcinoma (HCC) is one of the most common malignancies and the third leading cause of cancer-related death worldwide ([@b1-ol-0-0-10557]). The recurrence rate of HCC 5-years after surgery is \>60% in Japan ([@b2-ol-0-0-10557]). Studies have found that tumor heterogeneity, high degree of differentiation, large size, multicentricity, microvascular invasion, intraoperative extrusion of the tumor, postoperative intervention, macroscopic or microscopic portal venous tumor extension and intrahepatic metastasis were risk factors indicative of poor prognosis after surgery ([@b3-ol-0-0-10557]--[@b5-ol-0-0-10557]). Magnetic resonance imaging (MRI) provides valuable imaging information for the preoperative and postoperative evaluation of HCC ([@b6-ol-0-0-10557]).

Gadolinium-ethoxybenzyl diethylenetriamine pentaacetic (Gd-EOB-DTPA)-enhanced MRI has been widely used in the evaluation of HCC, as it aids in the differential diagnosis, grading and final diagnosis process ([@b7-ol-0-0-10557]--[@b9-ol-0-0-10557]). The uptake of Gd-EOB-DTPA in HCC is determined by the expression of organic anion transporter polypeptide 1B1 (OATP1B1) and OATPIB3, and their activity can predict the signal intensity of Gd-EOB-DTPA-MRI ([@b10-ol-0-0-10557]). A previous study found that dysplastic nodules (DN) reduced the uptake of Gd-EOB-DTPA and that the enhancement rate of DN in the hepatobiliary phase was higher compared with that in the moderately and poorly differentiated HCC ([@b11-ol-0-0-10557]). The advantage of Gd-EO-DTPA is that it is taken up by hepatocytes, resulting in the maximal enhancement of normal liver parenchyma in the hepatobiliary phase (HBP) 20 min after injection of the contrast agent ([@b12-ol-0-0-10557]), thus improving the detection rate of the lesion. A previous study by Zeng *et al* ([@b13-ol-0-0-10557]) found that Gd-EOB-DTPA-MRI significantly improved the diagnostic and accuracy rates of the liver focal lesions compared with multislice computed tomography and MRI non-specific gadolinium contrast. However, Gd-EOB-DTPA-MRI is inadequate to detect HCC for clinical treatment. Hence, evaluating the liver background and grading of the tumor are crucial factors for a better treatment. A previous study proved that dynamic contrast-enhanced (DCE)-MRI with Gd-EOB-DTPA as a liver-specific MR contrast agent can improve the sensitivity and accuracy in the detection of small HCC ([@b14-ol-0-0-10557]). In addition, An *et al* ([@b9-ol-0-0-10557]) reported that the enhanced degree of HCC on the early arterial phase was correlated with its histopathological grade by using multi-parameter quantitative analysis based on Gd-EOB-DTPA-enhanced MRI and diffusion-weighted imaging (DWI). However, the specificity of these multi-parameter methods for grading HCC in the aforementioned studies was not significant. T~1~ mapping based on Gd-EOB-DTPA-enhanced MRI has been increasingly used for qualitatively diagnosing diseases of hepatic fibrosis and liver function, and it has achieved good efficiency for discriminating between different degrees of liver fibrosis ([@b15-ol-0-0-10557]--[@b17-ol-0-0-10557]). Previous studies found that it was valuable to evaluate T~1~ mapping quantitatively at 5-, 10- and 20-min HBP after contrast enhancement for distinguishing interhepatic focal lesions ([@b16-ol-0-0-10557],[@b18-ol-0-0-10557]--[@b20-ol-0-0-10557]). Previously, retrospective studies demonstrated that T~1~ mapping before and after Gd-EOB-DTPA administration can benefit HCC grading, since T~1~ mapping could reflect the microscopic changes associated with the tumor to a certain extent ([@b16-ol-0-0-10557],[@b18-ol-0-0-10557]--[@b20-ol-0-0-10557]).

Up to now, there have been few T~1~ mapping studies on HCC grading focusing on the association between T~1~ mapping and HCC recurrence ([@b21-ol-0-0-10557]). The aim of the present study was to investigate the correlation between T~1~ mapping and the histopathological grade of HCC, which subsequently provides more preoperative diagnostic information by calculating the T~1~ value to predict the recurrence of HCC.

Materials and methods
=====================

### Patients

Retrospective data collection and analysis was approved by the Institutional Review Board of The First Affiliated Hospital of Guangxi Medical University (Nanning, China). A total of 75 consecutive patients who were diagnosed with primary HCC, confirmed by histopathological examination, between September 2015 and March 2017, were enrolled for the present study. All patients underwent a hepatectomy within 2 weeks of Gd-EOB-DTPA-enhanced MRI. Inclusion criteria were as follows: i) Patients who underwent Gd-EOB-DTPA-enhanced MRI before hepatectomy or liver biopsy; ii) patients who underwent surgical resection treatment; and iii) patients who were confirmed to have primary HCC by histopathological staining. Exclusion criteria were as follows: i) Tumor size \>1 cm; ii) previous interventional treatment; iii) metastasis; and iv) diffuse-type HCC. Recurrence was defined as a new lesion that was observed by two experienced radiologists on imaging (CT, MRI and ultrasound) or confirmed by pathology after rehepatectomy. All the patients were followed up until September 30, 2018, or until mortality. For patients who were unable to undergo reexamination in person at The First Affiliated Hospital of Guangxi Medical University, follow-up was performed 3 months after surgery, via telephone. Written informed consent was obtained from all patients with HCC. For the histopathological examination, the HCC tissues and corresponding non-cancerous were fixed in 4% neutral formaldehyde at 65°C for 2 h and subsequently the paraffin-embedded tissues were cut into 4 µm sections. Following which hematoxylin and eosin staining was performed for 1 h at room temperature. Pathological sections were observed under an Olympus BX53 light microscope (magnification, ×100 and ×200) and the features of HCC were observed as follows: The hepatocytes were polygonal or round, and arranged as nests or cables; the nuclei were enlarged and its nucleolus was deeply stained and there was an abundance of blood sinuses in the cancer nests.

### MRI protocols

All MR scans were conducted on a 3T MRI scanner (Magnetom Verio; Siemens Healthineers) with an 8-channel phased-array body coil. Half-fourier acquisition single-shot turbo spin echo sequence, axial turbo spin echo T2-weighted free breathing with fat suppression sequence, and breath-hold axial single-shot echo planar imaging DWI fat-suppressed sequence were performed prior to contrast enhancement. An axial T~1~-weighted three-dimensional spoiled gradient echo volume interpolated body examination fat-suppressed sequence was performed to acquire DCE-MRI data. A bolus of 0.025 mmol/kg Gd-EOB-DTPA (Bayer AG) was injected at a rate of 2 ml/sec through the cubital vein, followed by a 20-ml saline flush at the same rate. T~1~ mapping was performed before and at the 5, 10 and 20 min delay phases after Gd-EOB-DTPA administration. The sequence parameters used are listed in [Table I](#tI-ol-0-0-10557){ref-type="table"}.

### T~1~ value measurement

All MRI data obtained from the patients were analyzed to measure T~1~ relaxation time using operator-defined regions of interest (ROI). The ROI with an area of 1--1.2 cm^2^ was drawn manually on the lesion and non-tumorous liver parenchyma (1--2 cm distant from the margin of the tumor) by two experienced radiologists, respectively, who were blinded to the histopathological information, and each ROI was taken three times to measure the mean T~1~ values for further analysis. In case of conflicts, the decision was negotiated. All measurements were performed to avoid bile duct, hemorrhage, necrosis, cystic, fat, blood vessels and bile ducts, artifacts, selecting the maximum tumor cross-sectional area ([Fig. 1](#f1-ol-0-0-10557){ref-type="fig"}). Subsequently, the average values were calculated and the T~1~ value was expressed as the mean ± standard deviation (SD). The increasing rate of T~1~ value in the HCC lesion \[T1~(L-H)/H~ (%)\] was calculated using the following equation: T~1(L-H)/H~ (%)=(T~1L~-T~1H~)/T~1H~ ×100, where L indicates the lesion and H indicates the hepatic parenchyma. The T~1(L-H)/H~ (%) values before and at the 5-, 10- and 20-min HBP after Gd-EOB-DTPA administration for each patient were respectively calculated by the aforementioned equation.

### Statistical analysis

Analyses were performed using SPSS software (version 22.0; IBM Corp.). Statistical charts were created using GraphPad Prism v5.01 (Graphpad Software, Inc.). Descriptive statistics (mean ± SD), such as mean diameter were provided when no quantifiable data was available. One-way analysis of variance with the least significant difference test were used to compare the differences in the increment rate of the T~1~ value in the lesions relative to non-tumorous liver parenchyma \[T1~(L-H)/H~ (%)\] among different grades of HCC. Spearman\'s correlation analysis was used to evaluate the correlation between the increasing rate of T~1~ values and HCC grading. Patients who were lost to follow-up or died (due to an accident unrelated to HCC or from postoperative complications) during the follow-up period were censored. Receiver operating characteristic (ROC) curve analyses were conducted for T~1(L-H)/H~ (%) of grade I, II and III HCC. The cut-off values of T~1(L-H)/H~ (%) between grades I and II, grades II and III HCC were obtained, respectively; and then the cumulative recurrence rates of the three groups rearranged by these two cut-off values of T1~(L-H)/H~ (%) were also evaluated using Kaplan-Meier method and log-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

A total of 75 patients (66 men and 9 women; mean age, 52.89 years; age range, 23--79 years) with 81 lesions were included in the present study. According to the Liver Disease Symposium on Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma ([@b22-ol-0-0-10557]), the HCC cases were classified as BCLC stage A, B, C and D. A total of 81 lesions with a mean diameter of 4.13±0.32 cm (range 1.2--15 cm) were measured. Pathological diagnosis and grading were made according to the Edmondson-Steiner grading system ([@b23-ol-0-0-10557]). Due to research population restrictions, Edmondson-Steiner grade IV of HCC was not included in the present study. In our study, 19 patients with 21 lesions (25.93%) were classified as grade I, 37 patients with 40 lesions (49.38%) as grade II and 19 patients with 20 lesions (24.69%) as grade III. Recurrence of HCC was observed in 41 (54.67%) out of 75 patients during the follow-up period (median, 639.00 days; range, 42.00--973.00 days), and 1 patient was lost to follow-up after 490 days from the last reexamination. A total of 3 patients (2 HCC grade II and 1 HCC grade III) died 369, 195 and 398 days, respectively, after hepatectomy. The 41 recurrence cases \[grade I (n=5), grade II (n=23), and grade III (n=13)\] were verified by imaging (CT, MRI and ultrasound) or reoperation. The baseline characteristics of the patients are shown in [Table II](#tII-ol-0-0-10557){ref-type="table"}.

### Comparison of T~1~ mapping of different grades of HCC at different time points

On pre-contrast, T~1(L-H)/H~ (%) values for grade I, II and III HCC were 31.42±15.77, 56.07±21.42 and 78.21±27.68, respectively; at 5 min after enhancement, T~1(L-H)/H~ (%) values were 85.48±73.06, 132.63±37.27 and 172.82±71.48, respectively; at 10 min after enhancement, T1~(L-H)/H~ (%) values were 115.43±82.25, 190.81±66.58 and 226.13±101.49, respectively; and at 20 min after enhancement, T1~(L-H)/H~ (%) values were 149.46±97.32, 247.59±85.16 and 333.95±134.99, respectively. T~1(L-H)/H~ (%) was moderately correlated with Edmondson-Steiner HCC grading both at pre-contrast, and at 5, 10 and 20 min after administration of Gd-EOB-DTPA, respectively (r=0.637, r=0.554, r=0.499 and r=0.560, respectively; P\<0.001). On pre-contrast and on post-contrast at the 5- and 20-min HBP, multiple comparisons of T~1(L-H)/H~ (%) in the three groups of HCC were significantly different (P\<0.05). On post-contrast at 10 min, the differences in T~1(L-H)/H~ (%) value between grades I and II, and grades I and III were statistically significant (P\<0.05), while T1~(L-H)/H~ (%) values between grades II and III showed no significant differences (P\>0.05). The T~1(L-H)/H~ (%) value markedly increased for each grade of HCC at each time point and the T1~(L-H)/H~ (%) of different HCC grades increased after enhancement compared with pre-enhancement ([Fig. 2](#f2-ol-0-0-10557){ref-type="fig"}).

### Variation of T~1(L-H)/H~ (%) and the T~1~ relaxation time at each time point

The variation trend of T~1(L-H)\ /H~ (%) and the T~1~ relaxation time in HCC lesions and non-tumorous liver parenchyma of differentiation grades at each time point are shown in [Fig. 3](#f3-ol-0-0-10557){ref-type="fig"}. The value of T~1(L-H)/H~ (%) after enhancement was higher compared with that pre-contrast, and T1~(L-H)/H~ (%) was significantly increased with increasing delay time after contrast medium administration, with the most significant difference observed at the 20-min HBP (P\<0.05). For HCC lesions, the T~1~ value was lowest at 5 min, but increased gradually from 10 to 20 min, with overlapping results for grades II and III. For liver parenchyma, the higher the malignancy degree of HCC the lower the T~1~ value, particularly in the pre-contrast imaging. The T~1~ value of liver parenchyma decreased quickly from pre-contrast to 10 min post-enhancement, and then slowly from the 10- to 20-min HBP, for the three grades of HCC. However, the T~1~ value of non-tumorous liver parenchyma at each time point showed no statistical differences among the different grades of HCC (P\>0.05).

### Survival analysis for 3 groups of patients with HCC

At the 20-min HBP, the optimal cut-off point for the T1~(L-H)/H~ (%) of grade I and II, II and III HCC based on the ROC curve analysis were 155.15 and 241.20%, respectively ([Fig. 4](#f4-ol-0-0-10557){ref-type="fig"}). The patients were subsequently classified into a low group (T~1(L-H)/H~ (%) ≤155.15%), a medium group (T~1(L-H)/H~ (%) \>155.15% and T~1(L-H)/H~ (%) ≤ 241.20%) and a high group (T~1(L-H)/H~ (%) \>241.20%). During the follow-up period, 41 out of 75 patients developed recurrence; 5 cases (5/19) were Edmondson-Steiner grade I, 23 cases (23/37) were grade II and 13 cases (13/19) were grade III HCC, and their median recurrence times were undefined, 605 days and 258 days, respectively. The recurrence rates of patients with grade II and grade III HCC were significantly higher compared with that of patients with grade I HCC (P\<0.05) ([Fig. 5](#f5-ol-0-0-10557){ref-type="fig"}). The median recurrence time of the low T~1(L-H)/H~ (%) value group (n=17), the medium group (n=22) and the high group (n=37) were undefined, 530 days and 447 days, respectively. Recurrence rates also increased with increasing T~1(L-H)/H~ (%) from the low group to the medium and from the low to the high groups in the 20-min HBP (P\<0.05). The patients with HCC classified with low T1~(L-H)/H~ (%) values had lower cumulative recurrence rates compared with that in patients classified as medium and high value groups (P=0.028 and P=0.001, respectively). The cumulative recurrence rates of the patients with medium T1~(L-H)/H~ (%) values were lower compared with that of the high value group, but the results were not significantly different (P\>0.05) ([Fig. 6](#f6-ol-0-0-10557){ref-type="fig"}).

Discussion
==========

In the present study, Gd-EOB-DTPA-enhanced T~1~ mapping was used to quantitatively evaluate HCC. The results demonstrated that T~1(L-H)/H~ (%) was positively correlated with the Edmondson-Steiner grade of HCC. Gd-EOB-DTPA-enhanced T~1~ relaxation time-based parameter performed accurate diagnostic grading of HCC. Gd-EOB-DTPA has a T~1~ shortening effect and highlights the lesions in the liver. T~1~ relaxation time is an objective quantitative parameter. The T~1~ relaxation time was measured on the basis of the MR relaxation technique and is directly correlated with the concentration of Gd-EOB-DTPA ([@b24-ol-0-0-10557]). In the present study, the majority of patients with HCC had a history of chronic liver disease. The increment rate of the T~1~ value, which increased in the lesions relative to the non-tumorous liver parenchyma \[T~1(L-H)/H~ (%)\], reflects the true T~1~ relaxation time of the lesion. T~1(L-H)/H~ (%) was positively correlated with the Edmondson-Steiner grade of HCC. Due to the higher grade of HCC, the differences in liver function between tumor and normal liver parenchyma were more visible and the differences in the concentration of the Gd-EOB-DTPA in the tissue were markedly visible in the three grades of HCC at 5 min, 10 min and 20 min HBP after enhancement, respectively, leading to a higher rate-of-change of T~1~ values in the lesions when compared with that in non-tumorous liver parenchyma. Kogita *et al* ([@b11-ol-0-0-10557]) also confirmed that the concentration of Gd-EOB-DTPA uptake in HCC was positively associated with the degree of HCC differentiation. Moreover, the T1~(L-H)/H~ (%) was highest at the 20 min HBP in the present study, as the concentration of Gd-EOB-DTPA reached a peak value at 20 min after enhancement, while the concentration of the contrast agent in HCC cells remained lower.

In the present study, the T~1~ value of the non-tumorous liver parenchyma, especially on pre-contrast, was lower with a higher malignant degree of HCC (P\<0.05) and reached a peak at 20 min, which was similar to the result found in a previous study ([@b11-ol-0-0-10557]). The T~1~ value of grade I HCC was lowest at 5 min, and increased gradually at 10 and 20 min, with partly overlapping values in grade II and grade III HCC; however, the T~1(L-H)/H~ (%) of the three grades of HCC showed significant differences at pre-contrast, 5 min, and 20 min HBP, respectively. This result might be due to the liver background affecting the T~1~ value of the tumor. These results suggest that higher grades of HCC will uptake smaller amounts of Gd-EOB-DTPA, and that the absorption rate of the contrast agent is significantly different between HCC and non-tumorous liver parenchyma at different time points. This may be due to the absence of normal liver function for patients with HCC and due to the fact that Gd-EOB-DTPA is mainly observed in the extracellular space and intravascular area at the beginning of enhancement. Furthermore, the HCC cells uptake the contrast agents slowly, resulting in less uptake of the contrast agents into the cells, and the concentration of Gd-EOB-DTPA in the intracellular area increases gradually post-contrast. By contrast, the non-tumorous liver parenchyma uptakes Gd-EOB-DTPA faster than HCC, leading to two types of T~1~ value-time curves ([Fig. 3B and C](#f3-ol-0-0-10557){ref-type="fig"}).

With a higher degree of malignancy, new blood vessels are formed, which are more likely to invade the surrounding liver parenchyma, leading to recurrence ([@b25-ol-0-0-10557]). Previous studies have reported that HCC recurrence is related to heterogeneity, multicentric type and expression of vascular endothelial growth factor of the tumor ([@b26-ol-0-0-10557],[@b27-ol-0-0-10557]). In the present study, the patients with a higher grade of HCC had a higher recurrence rate. Patients with grade I HCC had the lowest cumulative recurrence rates compared with patients with grade II and III HCC. Patients with grade III HCC had a higher but indistinctive recurrence rate compared with that in patients with grade II HCC, which was \~800 days after resection. We hypothesized that the absence of a significant difference may be due to the small sample size for grade III HCC compared with that of grade II HCC, therefore, studies with a larger sample size are required in the future. This may also be due to tumorous microvascular invasion and the histological grade of the cirrhosis ([@b28-ol-0-0-10557]). It is possible that the recurrent tumor may invade the surrounding liver parenchyma, promote cellular density and increase the formation of new vessels. If the tumor invades the microvasculature of the surrounding liver parenchyma and local liver function is damaged, the excretion of Gd-EOB-DTPA can be blocked ([@b29-ol-0-0-10557],[@b30-ol-0-0-10557]). In addition, Zhou *et al* ([@b4-ol-0-0-10557]) reported that the Edmondson-Steiner grade of HCC was an independent risk factor for recurrence after resection. Mori *et al* ([@b31-ol-0-0-10557]) also demonstrated that poorly differentiated HCC was more likely to have intrahepatic metastasis and recurrence compared with well-/moderately differentiated HCC. The results from the present study revealed that the HCC patients with lower T~1(L-H)/H~ (%) values had lower cumulative recurrence rates compared with those patients with higher T~1(L-H)/H~ (%) values at the 20-min HBP. Shen *et al* ([@b32-ol-0-0-10557]) also recently found that a poorly differentiated tumor had a negative impact on the recurrence and long-term survival of patients with solitary HBV-associated HCCs after curative hepatectomy. This suggests that the lower the differentiation of HCC is, the more likely it is to recur, which was partly consistent with the study by Shen *et al* ([@b32-ol-0-0-10557]). Hence, if Gd-EOB-DTPA-enhanced MRI could be used to detect small lesions with high sensitivity, and grade HCC with Gd-EOB-DTPA-MRI T~1~ mapping before surgery, it will contribute to a more appropriate therapy for patients with HCC. Precise preoperative information regarding the characterization, prognosis and staging of HCC is essential.

However, the present study has several limitations. Firstly, the sample size is small, particularly for well- and poorly differentiated HCC. A further study with a larger sample size and longer follow-up time is required. Secondly, due to the small number of recurrent HCC patients, the effect of liver function, liver fibrosis and other liver backgrounds on the recurrence of HCC were not analyzed.

In conclusion, the parameters of T~1~ mapping, T~1(L-H)/H~ (%) are positively correlated with the degree of malignancy of HCC. Higher grade HCC has a higher recurrence rate. The recurrence rate of HCC patients with high T~1(L-H)/H~ (%) was consistently significantly higher compared with that of patients with low T~1(L-H)/H~ (%). Although a larger-scale prospective study is required to confirm these findings, the results showed that T~1~ mapping on Gd-EOB-DTPA-enhanced MRI was beneficial in HCC applications and provided valuable information for HCC grading and recurrence prediction.
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![Regions of interest in tumor and non-tumor liver parenchyma at different time points after HBP enhancement in 3 representative patients with Edmondson-Steiner grade I, II and III HCC. (A-D) T~1~ mapping of a 78-year old male patient with HCC grade I at (A) pre-contrast and at (B) 5, (C) 10 and (D) 20 min after administration of Gd-EOB-DTPA, respectively. (F-I) T~1~ mapping of a 62-year old male patient with HCC grade II at (F) pre-contrast and at (G) 5, (H) 10 and (I) 20 min after administration of Gd-EOB-DTPA, respectively. (K-N) T~1~ mapping of a 30-year old male patient with HCC grade III at (K) pre-contrast and at (L) 5, (M) 10 and (N) 20 min after administration of Gd-EOB-DTPA, respectively. (E, J and O) Hematoxylin and eosin staining images of grades I, II and III of HCC. (E) Grade I HCC at ×100 magnification. The tumor cells are arranged into irregular thick lines, which are more than three layers, indicated by the blue arrows. (J) Grade II HCC at ×200 magnification. The tumor cells are arranged in a disorderly manner with less atypia, as indicated by the blue arrows. (O) Grade III HCC at ×100 magnification, The lines of cancer cells were markedly thickened, as indicated by the blue arrows, and the atypical cancer cells showed enlarged nuclei with deeply stained nucleoli, as indicated by the red arrows. Pre, pre-contrast; HHC, hepatocellular carcinoma; Gd-EOB-DTPA, gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid.](ol-18-03-2322-g00){#f1-ol-0-0-10557}

![One-way analysis of variance was used to analyze the differences in T~1(L-H)/H~ (%) value in the 81 HCC lesions between different Edmondson-Steiner grades at pre-contrast, and 5, 10 and 20 min after administration of gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid, respectively. ^\#\#^P\<0.01 and ^\#\#\#^P\<0.001 vs. grade I; \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. grade II. Pre, pre-contrast; L, lesion; H, hepatic parenchyma; HHC, hepatocellular carcinoma.](ol-18-03-2322-g01){#f2-ol-0-0-10557}

![Variation trend of T~1(L-H)/H~ (%), and T~1~ relaxation time in HCC lesion and non-tumorous liver parenchyma of various differentiation grades at each time point. (A) T~1(L-H)/H~ (%) was increased with increasing time after administration, and the most significant difference was observed at 20 min in the HBP (P\<0.05). (B) T~1~ value of HCC was lowest at 5 min, but increased gradually from 10 to 20 min, with overlapping results for grades II and grade III. (C) T~1~ value of liver parenchyma declined rapidly from 5 to 10 min, and declined slowly from 10 to 20 min for grade I HCC, while that of grades II and III HCC declined slowly from 5 to 20 min HBP. This linear trend showed that the higher the grade of HCC, the shorter the T~1~ relaxation time of liver parenchyma and showed no statistically significant differences (P\>0.05). HHC, hepatocellular carcinoma.](ol-18-03-2322-g02){#f3-ol-0-0-10557}

![ROC curve of the optimal cut-off point for the T~1(L-H)/H~ (%) of grades I, II and III HCC. ROC curve of (A) grade I and II HCC, (B) grade II and III HCC, and (C) grade I and III HCC. ROC, receiver operating characteristic; AUC, area under the curve; Se, sensitivity; Sp, specificity; CI, confidence interval; HHC, hepatocellular carcinoma.](ol-18-03-2322-g03){#f4-ol-0-0-10557}

![Recurrence curve of three grades of HCC after surgery. Recurrence rates of grades II and III HCC were significantly higher compared with that of grade I HCC (P=0.023 and P=0.006, respectively). Patients with grade III HCC had higher recurrence rates compared with patients with grade II HCC, at 800 days after resection, but the differences were not significantly different (P\>0.05). HHC, hepatocellular carcinoma.](ol-18-03-2322-g04){#f5-ol-0-0-10557}

![Kaplan-Meier analysis and log-rank test was performed for the 3 groups classified according to the two cut-off T~1(L-H)/H~ (%) values of grades I and II, II and III HCC, 155.15 and 241.20%, respectively, at 20 min HBP. Recurrence curve showed the recurrence rates of HCC with low, medium and high T~1(L-H)/H~ (%) values following surgery.](ol-18-03-2322-g05){#f6-ol-0-0-10557}

###### 

Magnetic resonance imaging sequences used in the present study.

  Sequences                   Repetition time, msec   Echo time, msec   Flip angle, °   Slice thickness, mm   Matrix    Field of view, mm
  --------------------------- ----------------------- ----------------- --------------- --------------------- --------- -------------------
  Plain scan                                                                                                            
    T1WI, tra                 3.96                    1.41              9               4.5                   224×320   350×350
    In/outphase               171                     2.31              70              6                     192×256   380×380
    T2WI, tra                 2,930                   89                133             6                     240×320   400×400
    T2WI, cro                 1,800                   95                160             6                     224×320   380×380
    VIBE-T1 mapping           3.96                    1.41              2/15            4.5                   224×320   350×350
    DWI                       9,200                   66                                6                     118×148   420×420
  Dynamic contrast-enhanced                                                                                             
    T1WI, tra                 4.56                    1.48              30              4.5                   224×320   350×350
    T1WI, cor                 3.32                    1.17              9               4                     216×288   350×350
    VIBE-T1 mapping           3.96                    1.41              2/15            4.5                   224×320   350×350

T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; DWI, diffusion-weighted imaging; DCE, dynamic contrast-enhanced; VIBE, volumetric interpolated breath-hold examination; tra, transversal; cor, coronal.

###### 

Clinical characteristics of the 75 patients with primary hepatocellular carcinoma.

  Characteristic                                                                   Value
  -------------------------------------------------------------------------------- ------------
  Age, years^[a](#tfn2-ol-0-0-10557){ref-type="table-fn"}^                         52.89±1.38
  Sex, n (%)                                                                       
    Male                                                                           66 (88.00)
    Female                                                                         9 (12.00)
  Mean size, cm^[a](#tfn2-ol-0-0-10557){ref-type="table-fn"}^                      4.13±0.32
  Underlying disease, n (%)                                                        
    HBV                                                                            66 (88.00)
    HCV                                                                            8 (10.67)
    HBV + HCV                                                                      8 (10.67)
    Clonorchis                                                                     9 (12.00)
    Cirrhosis                                                                      44 (58.67)
  Child-Pugh classification^[b](#tfn3-ol-0-0-10557){ref-type="table-fn"}^, n (%)   
    A                                                                              70 (93.33)
    B                                                                              5 (6.67)
  BCLC stage, n (%)                                                                
    A                                                                              52 (69.33)
    B                                                                              17 (22.67)
    C                                                                              6 (8.00)
    D                                                                              0 (0.00)
  AFP, n (%)                                                                       
    Normal \<20 ng/ml                                                              27 (36.00)
    Abnormal ≥20 ng/ml                                                             48 (64.00)

Mean ± standard deviation

([@b33-ol-0-0-10557]). HBV, hepatitis B virus; HCV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein.

[^1]: Contributed equally
